Dr. Takahashi presents his findings from a study of 70 AML patients demonstrating clonal remodeling at relapse. Furthermore, divergent clones with a shared functionality were inferred by reconstructing the phylogeny of driver mutations in AML. Through single-cell analysis, which had 100% concordance with bulk sequencing, he was able to visualize co-occurrence of foundation mutations to identify cancer driver genes. In this presentation, he shows, through mutation tracking, that clonal heterogeneity is a reflection of how each clone evolves under pressure of the cancer ecosystem and treatment.
